SpinaFX Earns CE Mark for Triojection Spine System
TORONTO, July 16, 2026 SpinaFX Medical Inc. has achieved a significant regulatory milestone with the Medical Device Regulation (MDR)...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
TORONTO, July 16, 2026 SpinaFX Medical Inc. has achieved a significant regulatory milestone with the Medical Device Regulation (MDR)...
MINNEAPOLIS, Minn., July 13, 2026 HistoSonics has achieved a major international regulatory milestone after receiving CE Mark approval for...
AMSTERDAM, Netherlands, May 18, 2026 Royal Philips has introduced SmartIQ, a breakthrough AI-enabled coronary imaging technology developed for its...
MELBOURNE, Australia, and INDIANAPOLIS, May 15, 2026 Telix Pharmaceuticals Limited announced new strategic collaborations with EDAP TMS S.A. and...
